O

rphan drugs may target small patient populations, but they continue to rack up big numbers at the Food and Drug Administration.

Last year, the agency issued a record-breaking 77 orphan drug approvals, far exceeding the previous annual high of 49 approvals notched in 2014. At the same time, the FDA agreed to award a stunning 476 orphan designations, well above the 355 designations made in 2015, which was the previous record total. And there were 526 designation requests last year, second only to the record of 582 made in 2016.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • That is to be expected. They do not have any new drugs that are substantially better than the existing drugs and whatever they are bringing to the table are unaffordable. Question of survival and revenue generation is in their plate and they need decide how to proceed.

  • And Commission ScottG “questioned whether the financial incentives should be different for drugs that receive “secondary approvals.” ‘ How about, “Obviously, Commissioner.” But then again, he doesn’t write the laws, does he?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy